<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618094</url>
  </required_header>
  <id_info>
    <org_study_id>Prehab</org_study_id>
    <nct_id>NCT04618094</nct_id>
  </id_info>
  <brief_title>Prehabilitation in Patients Suffering From Gynecological Cancers</brief_title>
  <official_title>Feasibility and Acceptance of High Intensity Interval Training in the Prehabilitation of Patients Suffering From Gynecological Cancers - a Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In 2016, 2216 Austrian women (= 10% of all new cancer cases) were diagnosed with&#xD;
      gynecological tumors. Depending on stage and entity, a main primary therapy option is the&#xD;
      surgical tumor resection. In the phase of Prehabilitation (= the time frame from diagnosis to&#xD;
      surgical intervention) supportive therapy options such as individualized exercise&#xD;
      interventions potentially improve recovery and postoperative outcomes after surgical&#xD;
      interventions. The primary aim of this study is to investigate the feasibility and acceptance&#xD;
      of a prehabilitation training intervention with high-intensity interval training compared to&#xD;
      a conventional moderate intensity continuous training and a non-training collective.&#xD;
      Secondary goals are the investigation of the effectiveness of threshold-based intensity&#xD;
      prescriptions and the impact on quality of life, fatigue, anxiety, depression, sexuality and&#xD;
      ability to work.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adherence to the exercise intervention</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>rate of completed exercise sessions as a measure of feasibility and acceptance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular fitness</measure>
    <time_frame>4 to 8 Weeks</time_frame>
    <description>determined by VO2max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>workability</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>determined by the workability index questionnaire; minimum value 7, maximum value 49, higher values indicating better results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of life: questionnaire</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>determined by the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire, minimum value 30, maximum value 126, higher scores indicating higher quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>determined by the Hospital Anxiety and Depression Scale questionnaire, minimum value 14, maximum value 56, higher values indicating higher depression levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>handgrip strength</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>determined by the handgrip dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>determined by bioimpedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in mg/ml as a part of the evaluation for cardiovascular risk factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyreoglobulin</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in µg/ml as a part of the evaluation for cardiovascular risk factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin A1c</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in % as a part of the evaluation for cardiovascular risk factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain natriuretic peptide</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in pg/ml as a part of the evaluation for cardiovascular risk factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in µg/ml as a part of the evaluation for cardiovascular risk factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatin Kinase</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in U/l as a part of the evaluation for cardiovascular risk factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in mg/l as a part of the evaluation for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 1</measure>
    <time_frame>4 to 8 Weeks</time_frame>
    <description>Laboratory parameter in ng/ml as a part of the evaluation for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 6</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in ng/ml as a part of the evaluation for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor alpha</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Laboratory parameter in pg/ml as a part of the evaluation for inflammation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Prehabilitation</condition>
  <arm_group>
    <arm_group_label>High intensity interval group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate continous intensity group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>non-exercising group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bicycle ergometer training with different intensities</intervention_name>
    <description>Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.</description>
    <arm_group_label>High intensity interval group</arm_group_label>
    <arm_group_label>Moderate continous intensity group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histopathologically verified cervical carcinoma (ICD10-C53) or&#xD;
&#xD;
          -  endometrial carcinoma (ICD10-C54) or&#xD;
&#xD;
          -  ovarian carcinoma (ICD10-C56)&#xD;
&#xD;
          -  planned primary/adjuvant surgery or medical training therapy&#xD;
&#xD;
          -  oncological release for medical training therapy&#xD;
&#xD;
          -  Eastern cooperative oncology group performance status (ECOG) 0-II&#xD;
&#xD;
          -  Age &gt;18a to 80&#xD;
&#xD;
          -  mental aptitude to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  serious orthopaedic, rheumatological, neurological, oncological and cardiovascular&#xD;
             diseases which are incompatible with a training intervention&#xD;
&#xD;
          -  general contraindications for exercise ergometry according to the guidelines of the&#xD;
             austrian society of cardiology&#xD;
&#xD;
          -  osseous or cerebral metastasis&#xD;
&#xD;
          -  participation in a training study in the last year or already before cancer diagnosis&#xD;
             with high training volumes (&gt;150min moderate / &gt;75min more intensive endurance&#xD;
             training per week)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Palma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Palma, MD</last_name>
    <phone>434040023080</phone>
    <email>stefano.palma@meduniwien.ac.at</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Stefano Palma</investigator_full_name>
    <investigator_title>Principal Investigator, PhD student</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

